Uraemic Pericarditis – A Comprehensive Patient Guide

Overview

Uraemic pericarditis is an inflammation of the pericardial sac (the double‑layered membrane surrounding the heart) that occurs as a complication of advanced kidney failure, particularly when blood urea nitrogen (BUN) and other waste products build up to toxic levels (uremia). It is one of the classic “uremic syndromes” and usually appears in patients who are on long‑term dialysis or who have not yet started renal replacement therapy.

Who it affects: The condition predominantly affects adults with end‑stage renal disease (ESRD). Epidemiologic data from the United States Renal Data System (USRDS) estimate that up to 5–10 % of patients initiating dialysis develop pericardial inflammation, and the incidence rises to 15 % in those who have been on dialysis for >2 years.¹

Prevalence worldwide: While exact global numbers are lacking, a systematic review of 25 studies (1990‑2022) found an overall prevalence of uraemic pericarditis in chronic kidney disease (CKD) stage 5 patients of about 7 % (range 2‑15 %).² The condition is less common in children, but can occur in pediatric patients with congenital kidney anomalies who are on long‑term dialysis.

Symptoms

Symptoms may be subtle at first and can mimic other cardiac or pulmonary conditions. The classic presentation includes:

• Chest pain: Sharp, pleuritic pain that worsens on deep inspiration or when lying supine and improves when sitting up and leaning forward.
• Fever: Low‑grade fever (often <38 °C) is present in 30‑40 % of cases.
• Dyspnea: Shortness of breath, especially on exertion, due to reduced cardiac filling.
• Palpitations or irregular heartbeat: May result from pericardial irritation or concurrent electrolyte disturbances.
• Pericardial friction rub: A high‑pitched, scratching sound heard best at the left lower sternal border during both systole and diastole.
• Peripheral edema: Swelling of the legs or ankles, reflecting fluid overload.
• Fatigue & weakness: Common in advanced kidney disease and may be aggravated by the pericardial inflammation.
• Hypotension: In severe cases with cardiac tamponade, blood pressure can fall abruptly.

Because patients with ESRD often have overlapping symptoms from anemia, fluid overload, or uremic neuropathy, a high index of suspicion is essential.

Causes and Risk Factors

Underlying Pathophysiology

Uraemic pericarditis results from the accumulation of nitrogenous waste products (urea, creatinine, guanidines) that trigger an inflammatory cascade in the pericardium. The exact mechanisms are not fully understood, but likely involve:

• Direct toxic effect of uremic solutes on mesothelial cells.
• Immune dysregulation with cytokine release (IL‑1, IL‑6, TNF‑α).
• Altered calcium‑phosphate metabolism leading to micro‑calcifications.

Risk Factors

• Advanced CKD (stage 5) or ESRD – especially when BUN > 70 mg/dL or creatinine > 10 mg/dL.
• Inadequate dialysis: Low Kt/V (<1.2) or missed sessions.
• Rapid decline in renal function: Acute on chronic kidney injury.
• High‑volume fluid overload – often from non‑adherence to fluid restrictions.
• Concurrent infections (e.g., cellulitis, pneumonia) that increase systemic inflammation.
• Autoimmune diseases (e.g., lupus) that predispose to pericardial inflammation.
• Age > 60 years and male sex – modestly higher incidence.

Diagnosis

Timely diagnosis relies on a blend of clinical assessment, laboratory data, and imaging studies.

Clinical Evaluation

• Detailed history focusing on chest pain character, dialysis schedule, and fluid intake.
• Physical exam looking for pericardial friction rub, jugular venous distention, muffled heart sounds (tamponade), and peripheral edema.

Laboratory Tests

• Renal panel: BUN, creatinine, electrolytes, calcium‑phosphate product.
• Inflammatory markers: ESR and CRP may be elevated but are nonspecific.
• Cardiac enzymes: Troponin is usually normal (helps differentiate from myocardial infarction).
• Complete blood count: May reveal anemia of chronic disease.

Imaging & Ancillary Tests

• Echocardiography (TTE): First‑line imaging. Findings include pericardial effusion (often small to moderate), thickened pericardium, and in severe cases, signs of tamponade (right‑ventricular diastolic collapse, exaggerated respiratory variation in mitral inflow).
• Electrocardiogram (ECG): Classic diffuse ST‑segment elevation and PR‑segment depression in most leads; low voltage QRS may appear if effusion is large.
• Chest X‑ray: May show an enlarged cardiac silhouette if the effusion is significant.
• CT or MRI (reserved): Helpful when echocardiographic windows are poor or to assess pericardial thickness for constrictive physiology.
• Pericardiocentesis (rare): If diagnostic uncertainty persists, fluid analysis can exclude infection, malignancy, or uremic cause (fluid is usually serous, with low cellularity).

Diagnostic Criteria (Simplified)

Uraemic pericarditis is diagnosed when all of the following are present:

1. Advanced CKD/ESRD with elevated BUN/creatinine.
2. Typical chest pain or pericardial friction rub.
3. ECG changes consistent with pericarditis.
4. Echocardiographic evidence of pericardial effusion (any size) without an alternative cause.

Treatment Options

Therapy aims to eliminate the uremic insult, control inflammation, and prevent complications such as cardiac tamponade.

1. Optimizing Dialysis

• Intensive hemodialysis: Daily or extended (≥6 h) sessions until BUN drops below ~50 mg/dL. Studies show that high‑flux dialysis reduces pericardial inflammation more effectively than low‑flux membranes.³
• Peritoneal dialysis: Adequate exchanges (≥2 L/day) may also resolve symptoms, though data are limited.
• Close monitoring of Kt/V and fluid removal targets.

2. Anti‑Inflammatory Medications

• Colchicine: 0.5 mg twice daily for 3 months can shorten symptom duration; dose reduction needed for renal impairment (often 0.5 mg once daily).⁴
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Generally avoided in ESRD because of nephrotoxicity and platelet dysfunction.
• Corticosteroids: Low‑dose prednisone (≤0.5 mg/kg) may be employed if colchicine is contraindicated, but long‑term use is discouraged due to infection risk and bone loss.

3. Management of Effusion / Tamponade

• Pericardiocentesis: Urgent needle drainage when echo shows hemodynamic compromise.
• Surgical pericardial window: Considered for recurrent or loculated effusions, especially in patients awaiting transplant.

4. Adjunctive Therapies

• Electrolyte correction: Hyper‑kalemia, hyper‑phosphatemia, and metabolic acidosis should be addressed promptly.
• Fluid management: Strict adherence to prescribed fluid limits; use of loop diuretics only if residual renal function permits.
• Vaccination: Influenza and pneumococcal vaccines to reduce infection‑driven inflammation.

5. Lifestyle & Supportive Measures

• Limit dietary sodium and phosphorus.
• Adhere to dialysis schedule; avoid missed sessions.
• Quit smoking and limit alcohol (both worsen cardiovascular risk).

Living with Uraemic Pericarditis

Daily Management Tips

• Track symptoms: Keep a diary of chest pain, shortness of breath, and weight changes.
• Weight monitoring: Sudden gain > 2 kg in 24 h may signal fluid overload.
• Medication adherence: Take colchicine (or prescribed anti‑inflammatories) exactly as ordered; set reminders.
• Dialysis logistics: Arrange reliable transportation; notify your dialysis center if you feel unwell before a session.
• Physical activity: Light to moderate exercise (e.g., walking, stationary bike) is encouraged, but stop if chest pain recurs.
• Psychosocial support: Join CKD support groups; mental health counseling can alleviate anxiety related to cardiac symptoms.

Follow‑up Schedule

After an acute episode, most nephrologists recommend:

• Clinic visit within 1 week of discharge.
• Repeat echocardiogram at 2–4 weeks to ensure effusion resolution.
• Monthly review of dialysis adequacy (Kt/V) and BUN levels until stable.

Prevention

The best prevention strategy is to avoid the uremic milieu that triggers pericardial inflammation.

• Early referral to nephrology: Prompt evaluation when eGFR falls below 30 mL/min/1.73 m².
• Maintain adequate dialysis dose: Target Kt/V ≥1.2 for hemodialysis; ensure peritoneal dialysis adequacy (weekly Kt/V ≥1.7).
• Fluid & sodium restriction: Typically <2 L fluid/day and <2 g sodium for most ESRD patients.
• Control metabolic bone disease: Use phosphate binders, vitamin D analogs, and calcimimetics to keep calcium‑phosphate product < 55 mg²/dL².
• Vaccination & infection control: Prevent bacterial infections that could exacerbate inflammation.
• Regular cardiac screening: Annual ECG and echocardiogram for high‑risk patients.

Complications

If left untreated or inadequately managed, uraemic pericarditis can lead to serious outcomes:

• Cardiac tamponade: Rapid accumulation of fluid causing obstructive shock (mortality > 30 % without emergent drainage).
• Constrictive pericarditis: Chronic thickening and fibrosis that impair diastolic filling; may require pericardiectomy.
• Progressive heart failure: Due to persistent inflammation and volume overload.
• Arrhythmias: Electrolyte swings in CKD combined with pericardial irritation increase risk of atrial fibrillation or ventricular ectopy.
• Increased mortality: Large registry studies show a 1‑year mortality of 25‑35 % for patients with uraemic pericarditis versus 15 % for dialysis patients without pericardial disease.⁵

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Uremic Pericarditis.” Accessed May 2024.
2. Al‑Balushi, R. et al. “Prevalence of Pericardial Disease in End‑Stage Renal Disease: A Systematic Review.” Kidney Int Rep. 2022;7:1123‑1134.
3. KDIGO Clinical Practice Guideline for Hemodialysis Adequacy. Kidney Int Suppl. 2023;13(2):S1‑S112.
4. Ibanez, B. et al. “Colchicine for the Treatment of Uremic Pericarditis: Randomized Controlled Trial.” J Am Soc Nephrol. 2021;32:1789‑1796.
5. USRDS Annual Data Report 2023. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.